Humacyte, Inc.

Equities

HUMA

US44486Q1031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.99 ^USD	+2.31%		+7.84%	+40.49%

Mar. 28	Transcript : Humacyte, Inc. - Special Call
Mar. 22	Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024

Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 22, 2024 at 07:06 am EDT

Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.

Latest news about Humacyte, Inc.

Transcript : Humacyte, Inc. - Special Call	Mar. 28
Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024	Mar. 22
Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	Mar. 22	MT
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	Mar. 08	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	Mar. 01	MT
Humacyte Prices $40.2 Million Share Offering	Mar. 01	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Feb. 09	MT
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	Feb. 09	DJ
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	Feb. 09	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	Feb. 09	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	Feb. 09	CI
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	Dec. 12	MT
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	Dec. 12	CI
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	Dec. 11	MT
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	Nov. 17	CI
Transcript : Humacyte, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	23-10-16	CI
Humacyte Jumps 8.2% After Hours Thursday; CEO Laura Niklason, CFO Dale Sander to Present at Cantor Global Healthcare Conference Sept. 28	23-09-22	MT
Transcript : Humacyte, Inc. - Special Call	23-09-20

Chart Humacyte, Inc.

Duration

Period

More charts

Company Profile

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.99 USD

Average target price

8 USD

Spread / Average Target

+100.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMACYTE, INC.	+40.49%	475M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research